Biotech RadarJobs updated

COMPANY

Ascentage Pharma

HQ: Rockville, MD (US office) source · ascentage.com ↗ · Mid-Atlantic

Clinical Phase 3

Keywords: oncology CLL/SLL Chronic Lymphocytic Leukemia Non Hodgkin Lymphoma Chronic Myeloid Leukemia Small Lymphocytic Lymphoma Acute Myeloid Leukemia Multiple Myeloma Small Cell Lung Cancer CML Neuroblastoma Relapsed/Refractory Hematological Malignancies Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation) Relapsed/Refractory Mantle Cell Lymphoma (MCL) Relapsed/Refractory Waldenström Macroglobulinemia (WM) Relapsed/Refractory Marginal Zone Lymphoma (MZL) Relapsed/Refractory Follicular Lymphoma (FL) Non Small Cell Lung Cancer Esophageal Cancer Ovarian Cancer Malignant Pleural Mesothelioma GIST Platinum-resistant Recurrent Ovarian Cancer Ph+ ALL Leukemia, Lymphoblastic, Acute, Philadelphia-Positive Relapsed/Refractory Acute Myeloid Leukaemia Myeloid Malignancy Anemia Gastrointestinal Stromal Tumor Advanced Pancreatic Cancer SLE Higher-risk Myelodysplastic Syndrome Leukemia, Myeloid, Chronic Myeloid Leukemia Philadelphia Positive Acute Lymphoblastic Leukemia B Cell Precursor Type Acute Leukemia

Location: Rockville, MD (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

53Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: A Study of APG-3288 in Relapsed/Refractory Blood Cancers source ↗
  2. Trial start Phase 1: Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment source ↗
  3. Trial start Phase 3: Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). source ↗
  4. Trial start Phase 1: APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST source ↗
  5. Trial start Phase 3: A Study of Olverembatinib in SDH-deficient GIST. source ↗
  6. Trial start Phase 1/Phase 2: A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. source ↗
  7. Trial start Phase 3: A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia source ↗
  8. Trial start Phase 3: A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. source ↗
  9. Trial start Phase 3: Study of Olverembatinib (HQP1351) in Patients With CML-CP source ↗
  10. Trial start Phase 3: Global Trial in APG2575 for Patients With CLL/SLL source ↗
  11. Trial start Phase 3: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) source ↗
  12. Trial start Phase 1: A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918. source ↗
  13. Trial start Phase 1/Phase 2: APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors source ↗
  14. Trial start Phase 1: Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas source ↗
  15. Trial start Phase 1: The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects source ↗
  16. Trial start Phase 1/Phase 2: APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma source ↗
  17. Trial start Phase 1: A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors source ↗
  18. Trial start Phase 2: Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL source ↗
  19. Trial start Phase 1/Phase 2: APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma source ↗
  20. Trial start Phase 1/Phase 2: A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer source ↗
  21. Trial start Phase 1/Phase 2: A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) source ↗
  22. Trial start Phase 2: A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL source ↗
  23. Trial start Phase 1: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia source ↗
  24. Trial start Phase 1/Phase 2: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors source ↗
  25. Trial start Phase 1/Phase 2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma source ↗

Showing 25 of 49 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) Showing 50 of 53

RecordTitlePhaseStatusStartPrimary completion
NCT06423911Study of Olverembatinib (HQP1351) in Patients With CML-CPPhase 3RecruitingFeb 5, 2024Jun 30, 2027 (estimated)
NCT05701306APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid TumorsPhase 1/Phase 2RecruitingFeb 28, 2023Jun 1, 2027 (estimated)
NCT07424833A Study of APG-3288 in Relapsed/Refractory Blood CancersPhase 1Recruiting2026-082029-12 (estimated)
NCT06319456A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.Phase 3RecruitingApr 7, 20242027-08 (estimated)
NCT03917043APG-2449 in Patients With Advanced Solid TumorsPhase 1RecruitingMay 27, 20192027-12 (estimated)
NCT06640361A Study of Olverembatinib in SDH-deficient GIST.Phase 3RecruitingNov 11, 2024Mar 31, 2027 (estimated)
NCT06687070APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STPhase 1RecruitingDec 17, 20242027-05 (estimated)
NCT06104566Global Trial in APG2575 for Patients With CLL/SLLPhase 3RecruitingDec 20, 2023Dec 31, 2026 (estimated)
NCT03913949A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesPhase 1Active, not recruitingJun 3, 2019Oct 20, 2024 (actual)
NCT06051409A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)Phase 3RecruitingAug 31, 2023Dec 31, 2027 (estimated)
NCT04501120Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AMLPhase 1/Phase 2RecruitingSep 28, 20202028-09 (estimated)
NCT05773586A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.Phase 1RecruitingMar 13, 2023Dec 31, 2027 (estimated)
NCT03594422A Study of HQP1351 in Patients With GIST or Other Solid TumorsPhase 1RecruitingJul 11, 20182027-12 (estimated)
NCT05147467Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLPhase 2RecruitingDec 28, 20212026-12 (estimated)
NCT04284488Dose-escalation Study of APG-1387 and Toripalimab in Solid TumorsPhase 1/Phase 2TerminatedApr 10, 2020Nov 30, 2024 (actual)
NCT04643405APG-1387 Plus Chemotherapy in Advanced Pancreatic AdenocarcinomaPhase 1/Phase 2TerminatedMar 17, 2021Jun 25, 2024 (actual)
NCT07282093Pharmacokinetics of Olverembatinib in Participants With Hepatic ImpairmentPhase 1RecruitingNov 11, 2025Jun 30, 2026 (estimated)
NCT06182969A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.Phase 1/Phase 2RecruitingAug 9, 20242026-04 (estimated)
NCT06389292A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaPhase 3RecruitingJun 11, 2024May 25, 2028 (estimated)
NCT06641414Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).Phase 3RecruitingJan 22, 20252029-06 (estimated)
NCT04260022Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLPhase 1RecruitingJan 9, 2020Dec 27, 2029 (estimated)
NCT04496349A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLPhase 2RecruitingJul 12, 2021May 31, 2026 (estimated)
NCT04001777A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC PatientsPhase 1Active, not recruitingJul 4, 20192025-12 (estimated)
NCT04260217APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström MacroglobulinemiaPhase 1CompletedMay 30, 2021Feb 5, 2024 (actual)
NCT03611868A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsPhase 1/Phase 2Active, not recruitingAug 29, 2018Dec 30, 2025 (estimated)
NCT04893759A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine TumorsPhase 1TerminatedJan 6, 2022Sep 14, 2022 (actual)
NCT04494503Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLPhase 1/Phase 2RecruitingAug 31, 2020Oct 20, 2024 (actual)
NCT04215809Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLLPhase 1RecruitingMar 2, 2020Oct 31, 2025 (estimated)
NCT04126681A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhasePhase 2CompletedOct 21, 2019Aug 1, 2024 (actual)
NCT04785196APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid TumorsPhase 1/Phase 2RecruitingMay 26, 20212026-04 (estimated)
NCT04275518A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.IRecruitingJul 6, 2020Dec 31, 2025 (estimated)
NCT03537482APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic MalignanciesEarly phase 1Unknown status (ClinicalTrials.gov)Aug 7, 2018Sep 15, 2024 (estimated)
NCT04946864A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast CancerPhase 1/Phase 2SuspendedAug 13, 2021Aug 12, 2024 (actual)
NCT05594758Named Patient Program for Olverembatinib (HQP1351)Not listedAvailableNot listedNot listed
NCT04358393A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDSPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Dec 4, 2020Dec 30, 2024 (estimated)
NCT05517616The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy SubjectsPhase 1CompletedSep 14, 2022Nov 1, 2022 (actual)
NCT05186012APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin LymphomaPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Jun 14, 20222025-09 (estimated)
NCT04964518A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)Phase 1/Phase 2Unknown status (ClinicalTrials.gov)Jul 30, 2021Jul 30, 2024 (estimated)
NCT04942067APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple MyelomaPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Dec 23, 2021Sep 1, 2024 (estimated)
NCT03883100A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I MutationWUnknown status (ClinicalTrials.gov)Apr 8, 20192024-04 (estimated)
NCT03883087A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I MutationWUnknown status (ClinicalTrials.gov)Apr 8, 20192024-05 (estimated)
NCT04674514APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Apr 13, 20212024-01 (estimated)
NCT03386526APG-1387 in Patients With Advanced Solid Tumors or Hematologic MalignanciesPhase 1CompletedNov 21, 2017Oct 31, 2022 (actual)
NCT05415098Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or LymphomasPhase 1Unknown status (ClinicalTrials.gov)Sep 30, 2022Sep 30, 2024 (estimated)
NCT04354727A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial TherapyPhase 1/Phase 2WithdrawnDec 15, 2020Dec 15, 2022 (estimated)
NCT04210037Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung CancerPhase 1/Phase 2TerminatedAug 20, 2020Aug 30, 2021 (actual)
NCT03080311A Study of APG-1252 in Patients With SCLC or Other Solid TumorsPhase 1CompletedFeb 12, 2017Jun 22, 2020 (actual)
NCT02935907APG-115 in Patients With Advanced Solid Tumors or LymphomasPhase 1Completed2016-10Jun 28, 2019 (actual)
NCT03585322APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis BPhase 1CompletedJul 4, 2018Oct 15, 2021 (actual)
NCT04126707The Absorption, Metabolism and Excretion of [14C] HQP1351 in HumansPhase 1CompletedNov 19, 2019Jan 13, 2020 (actual)
Feedback